Pulmonary Hypertension refers to abnormally elevated pressure within the pulmonary circulation and is a haemodynamic condition rather than one single disease. It is defined according to measurements obtained during right-heart catheterisation, with contemporary definitions based on mean pulmonary artery pressure above the accepted threshold at rest and further haemodynamic measurements used to distinguish different forms. The term is often confused with pulmonary arterial hypertension, but the latter is a specific subgroup within the broader category. Pulmonary Hypertension can arise from disease of the pulmonary arteries themselves, left-heart disease, lung disease or hypoxia, chronic obstruction of pulmonary vessels by organised clots, or several other mechanisms. Correct classification is essential because treatment differs substantially among these forms.
The pulmonary circulation normally operates at relatively low pressure because the lungs are a high-compliance vascular bed designed to receive the entire cardiac output. When pulmonary vascular resistance rises or pressure is transmitted backward from the left side of the heart, the right ventricle must work harder to pump blood through the lungs. Persistent pressure overload can cause right-ventricular hypertrophy, dilation and eventually right-heart failure.
In pulmonary arterial hypertension, narrowing and remodelling of small pulmonary arteries can result from abnormal proliferation of vascular cells, endothelial dysfunction, vasoconstriction and inflammatory processes. In other forms, the mechanisms differ; for example, left-heart disease can raise pulmonary venous and capillary pressures, while chronic thromboembolic disease physically obstructs portions of the pulmonary vascular bed.
Symptoms often develop gradually and may initially be non-specific. Exertional breathlessness is common, along with fatigue, reduced exercise capacity, chest discomfort, dizziness or fainting, particularly when the right ventricle cannot increase output sufficiently during exertion. As disease progresses, peripheral oedema, abdominal swelling and other signs of right-sided heart failure can appear. Because early symptoms overlap with common conditions such as asthma, deconditioning, obesity, anaemia and ordinary cardiovascular disease, diagnosis can be delayed. Clinical assessment may identify abnormal heart sounds, signs of fluid retention or reduced oxygenation, but physical examination alone cannot establish the haemodynamic diagnosis. The severity of symptoms reflects not only pulmonary artery pressure but also right-ventricular adaptation, cardiac output, oxygenation and the underlying cause.
Investigation usually begins with non-invasive testing such as electrocardiography, chest imaging, blood tests, lung-function testing and echocardiography. Echocardiography can estimate the probability of Pulmonary Hypertension and evaluate right- and left-heart structure and function, but it does not replace direct haemodynamic measurement when definitive diagnosis is required. Right-heart catheterisation measures pressures and cardiac output and allows calculation of pulmonary vascular resistance, making it the reference method for haemodynamic classification.
Additional testing may investigate lung disease, chronic thromboembolic disease, connective-tissue disorders, congenital heart disease or other underlying causes. A ventilation-perfusion scan can be particularly useful when chronic thromboembolic disease is suspected. The diagnostic process is therefore a classification exercise as much as a search for elevated pressure.
Pulmonary Hypertension is divided clinically into several major groups based on mechanism. Pulmonary arterial forms involve primarily the pulmonary arteriolar circulation and include idiopathic disease, heritable forms, drug-associated disease and forms associated with conditions such as connective-tissue disease or certain congenital heart disorders. Pulmonary Hypertension associated with left-heart disease is related to elevated pressures on the left side of the circulation.
Disease associated with lung conditions or chronic hypoxia represents another group, while chronic thromboembolic obstruction constitutes a distinct category because selected patients may benefit from procedures that remove or bypass vascular obstruction. Other mechanisms include multifactorial conditions. These categories are clinically important because a medicine appropriate for pulmonary arterial hypertension may not benefit, and can sometimes be inappropriate for, people whose Pulmonary Hypertension has a different mechanism.
Treatment therefore depends on classification rather than simply the numerical pressure measurement. General management can include treatment of the underlying disease, appropriate management of fluid balance, oxygen therapy for selected patients with hypoxaemia and supervised physical rehabilitation. In pulmonary arterial hypertension, specialist therapies may target pathways involving endothelin signalling, nitric oxide signalling or prostacyclin biology, sometimes using combinations of medicines.
Chronic thromboembolic disease can be treated in selected patients with pulmonary endarterectomy, balloon pulmonary angioplasty or targeted medical therapy depending on anatomy and operability. Advanced disease may lead to consideration of transplantation in carefully selected cases. Treatment decisions require specialist assessment because medication selection, anticoagulation, oxygen use and procedural options depend heavily on the specific cause and haemodynamic profile.
The prognosis of Pulmonary Hypertension varies greatly between subtypes and individuals. Some forms can be substantially improved by treating the underlying cause, while progressive pulmonary vascular disease can remain serious despite modern therapies. Right-ventricular function is particularly important because the right ventricle must adapt to increased afterload, and eventual failure of this adaptation is a major determinant of clinical deterioration.
Modern risk assessment integrates symptoms, exercise capacity, biomarkers, imaging, haemodynamics and right-heart function rather than relying on pulmonary artery pressure alone. Research has increasingly shifted from simply lowering measured pressure towards improving pulmonary vascular structure, preserving right-ventricular function and identifying patients who respond differently to targeted treatments. Early referral to a specialist centre can therefore be important when the condition is suspected or confirmed.
A common misconception is that Pulmonary Hypertension is simply high blood pressure occurring in the lungs in the same sense that systemic hypertension affects the body's arterial circulation. The two are physiologically different conditions with different causes and treatments. Another misconception is that a high pulmonary artery pressure automatically means pulmonary arterial hypertension; the broader category contains several mechanisms.
Pulmonary Hypertension can also occur secondary to otherwise recognisable heart or lung disease, and the underlying disorder may be the principal therapeutic target. Accurate diagnosis consequently requires more than detecting an elevated echocardiographic estimate. The condition is best understood as a family of haemodynamic disorders in which abnormal pressure or resistance in the pulmonary circulation places increasing demands on the right side of the heart.
